Log in

Clovis Oncology (NASDAQ:CLVS) Cut to "Strong Sell" at BidaskClub

Last updated on Thursday, August 13, 2020 | 2020 MarketBeat

Clovis Oncology (NASDAQ:CLVS) was downgraded by equities researchers at BidaskClub from a "sell" rating to a "strong sell" rating in a report released on Thursday, BidAskClub reports.

Several other equities analysts have also recently issued reports on the stock. Royal Bank of Canada restated a "buy" rating and set a $17.00 target price on shares of Clovis Oncology in a research note on Monday, April 20th. HC Wainwright reiterated a "buy" rating on shares of Clovis Oncology in a research note on Thursday, August 6th. Piper Sandler increased their price objective on shares of Clovis Oncology from $5.25 to $6.00 and gave the stock a "neutral" rating in a research note on Wednesday, May 6th. SVB Leerink lowered their price objective on shares of Clovis Oncology from $5.00 to $4.00 and set an "underperform" rating on the stock in a research note on Wednesday, May 20th. Finally, Bank of America cut shares of Clovis Oncology from a "neutral" rating to an "underperform" rating in a research note on Sunday, April 19th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the stock. Clovis Oncology currently has an average rating of "Hold" and a consensus target price of $11.07.

CLVS opened at $4.90 on Thursday. The stock has a market capitalization of $388.35 million, a P/E ratio of -0.81 and a beta of 2.40. The company's 50-day simple moving average is $6.38 and its two-hundred day simple moving average is $7.32. Clovis Oncology has a 52-week low of $2.93 and a 52-week high of $17.37.

Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.04) by ($0.11). Research analysts forecast that Clovis Oncology will post -4.13 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Ameritas Investment Partners Inc. grew its holdings in Clovis Oncology by 61.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,387 shares of the biopharmaceutical company's stock valued at $43,000 after buying an additional 2,420 shares in the last quarter. Evoke Wealth LLC purchased a new stake in Clovis Oncology during the 1st quarter valued at approximately $64,000. Moloney Securities Asset Management LLC purchased a new stake in Clovis Oncology during the 1st quarter valued at approximately $70,000. Cambridge Investment Research Advisors Inc. purchased a new stake in Clovis Oncology during the 1st quarter valued at approximately $72,000. Finally, Amalgamated Bank purchased a new stake in Clovis Oncology during the 2nd quarter valued at approximately $78,000. 44.18% of the stock is owned by institutional investors and hedge funds.

About Clovis Oncology

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Read More: What is the market perform rating?

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

10 Stocks to Buy On Fears of a Second Coronavirus Wave

Ever since the U.S. economy began to re-open (and honestly before that), there was concern over the impending “second wave” of the novel coronavirus. And although the second wave of the virus was not expected to hit until the fall, the concerns have been escalating as case numbers rise in multiple states.

And despite the Trump administration’s vehement statements that the economy would not shut down, we learned on February 25 that Texas was now pausing, and in some cases rolling back, its reopening measures in an effort to stem the spread of the virus.

And this is happening as the Centers for Disease Control (CDC) is now saying that it’s possible that 20 million Americans may have the coronavirus based on a sample of blood tests that are showing who has the antibodies in their system.

For its part, the stock market reacted sharply to the move. It was a move that undoubtedly frustrated many weary investors. In fact, you might be among those that have had just about enough of the Covid-19 market. I understand, I’m there too.

But, institutional investors are forward-looking. And right now, they don’t like what they. So stocks are having another broad selloff. However, in the midst of any selloff, there is money to be made. And the good news for investors is that many of the same stocks that were good buys in March, are still the stocks to buy right now. And while some of these stocks fit the classic definition of defensive stocks, you’ll find a few genuine growth stocks included on this list as well.

View the "10 Stocks to Buy On Fears of a Second Coronavirus Wave".

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.